What's Happening

Stay up to date on pharmaceutical developments, industry issues, and what’s happening with Healthesystems

Events

Healthesystems’ conferences and speaking engagements

WCI Annual Conference

August 21-24, 2022 in Orlando Florida

Visit Healthe in booth #913 to learn more about our workers’ comp pharmacy & ancillary benefits

National Comp (NWCD Conference)

October 19-21, 2022 Las Vegas, Nevada

Visit Healthe in booth #621 to participate in our Annual Industry Survey for a chance to win $500

Attend our VP of Clinical Services, Dr. Silvia Sacalis’ session on Thursday 10/20 @ 2pm: “Building an Employee Culture of Well-Being and Trust Amid COVID and Beyond”

MedMonitor

An up-to-date timeline of FDA approvals that could impact workers' comp
View All MedMonitor Information

Belbuca® (buprenorphine) buccal film

Approval Date: Aug 2021

Note: First-Time Generic

This is the first time a generic has been approved for Belbuca. For the management of pain severe enough to require daily, around the clock, long-term opioid treatment for which alternative treatment options are inadequate

hello world!

Semglee® (insulin glargine-yfgn) injection for subcutaneous use

Approval Date: Jul 2021

Note: New Product

This is the first time a generic has been approved for Semglee. For the treatment of Type 1 and Type 2 diabetes, this drug is both a biosimilar to, and interchangeable with Lantus (insulin glargine)

hello world!

WEGOVY (SEMAGLUTIDE) INJECTION

Approval Date: Jun 2021

Note: New Product

For chronic weight management with obesity or overweight with at least one weight-related condition (such as high blood pressure, type 2 diabetes, or high cholesterol) for use in addition to a reduced calorie diet and increased physical activity

hello world!

ADUHELM (ADUCANUMAB-AVWA) INJECTION

Approval Date: Jun 2021

Note: New Product

A first-of-its-kind, biologic treatment for Alzheimer’s disease. This drug is the first new Alzheimer’s drug since 2003

hello world!

Xeljanz® (tofacitnib) tablets

Approval Date: Jun 2021

Note: First-Time Generic

This is the first time a generic has been approved for Xeljanz. For the treatment of moderate-to-severe active rheumatoid arthritis, and psoriatic arthritis

hello world!

Kaletra® (lopinavir and ritonavir) tablets

Approval Date: Jun 2021

Note: First-Time Generic

This is the first time a generic has been approved for Kaletra. For the treatment of HIV-1 infection

hello world!

Intelence® (etravirine) tablets

Approval Date: Jun 2021

Note: First-Time Generic

This is the first time a generic has been approved for Intelence. For the treatment of HIV-1 infection in treatment-experienced patients

hello world!

Perforomist® (formoterol fumarate) inhalation solution

Approval Date: Jun 2021

Note: First-Time Generic

This is the first time a generic has been approved for Perforomist. For the maintenance treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema

hello world!

Brovana® (arformoterol tartrate) inhalation solution

Approval Date: Jun 2021

Note: First-Time Generic

This is the first time a generic has been approved for Brovana. For the long-term, twice daily administration in the maintenance of bronchoconstriction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema

hello world!

Aptiom® (eslicarbazepine acetate) tablets

Approval Date: Jun 2021

Note: First-Time Generic

This is the first time a generic has been approved for Aptiom. For the adjunctive treatment of partial-onset seizures

hello world!

Social Hub

Check out our latest posts and activity
View All Social Media
    lockenvelopephone-handsetmenucross-circle